159 related articles for article (PubMed ID: 32362347)
1. Possible Influence of the Route of Treatment Administration on Treatment Adherence in Patients With Multiple Sclerosis.
Sánchez Martínez I; Cerdán Sánchez M; López Román J; Iniesta Martínez F; Carreón-Guarnizo E; Meca Lallana JE; Zafrilla Rentero P
Clin Ther; 2020 May; 42(5):e87-e99. PubMed ID: 32362347
[TBL] [Abstract][Full Text] [Related]
2. Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.
Cutter G; Veneziano A; Grinspan A; Al-Banna M; Boyko A; Zakharova M; Maida E; Pasic MB; Gandhi SK; Everts R; Cordioli C; Rossi S
Mult Scler Relat Disord; 2019 Aug; 33():13-21. PubMed ID: 31132664
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
[TBL] [Abstract][Full Text] [Related]
4. Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD.
Cutter G; Veneziano A; Grinspan A; Al-Banna M; Boyko A; Zakharova M; Maida E; Pasic MB; Gandhi SK; Everts R; Cordioli C; Rossi S
Mult Scler Relat Disord; 2020 May; 40():101957. PubMed ID: 32028117
[TBL] [Abstract][Full Text] [Related]
5. Assessment of medication adherence and treatment satisfaction in Japanese patients with psoriasis of various severities.
Ichiyama S; Ito M; Funasaka Y; Abe M; Nishida E; Muramatsu S; Nishihara H; Kato H; Morita A; Imafuku S; Saeki H
J Dermatol; 2018 Jun; 45(6):727-731. PubMed ID: 29356075
[TBL] [Abstract][Full Text] [Related]
6. Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study).
Jongen PJ; Lemmens WA; Hoogervorst EL; Donders R
Health Qual Life Outcomes; 2017 Mar; 15(1):50. PubMed ID: 28292329
[TBL] [Abstract][Full Text] [Related]
7. Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.
Kleiter I; Lang M; Jeske J; Norenberg C; Stollfuß B; Schürks M
BMC Neurol; 2017 Sep; 17(1):174. PubMed ID: 28877664
[TBL] [Abstract][Full Text] [Related]
8. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
[TBL] [Abstract][Full Text] [Related]
9. Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS.
de Flon P; Laurell K; Söderström L; Gunnarsson M; Svenningsson A
Mult Scler; 2017 Aug; 23(9):1249-1257. PubMed ID: 27780912
[TBL] [Abstract][Full Text] [Related]
10. Adherence and satisfaction with oral hypoglycemic medications: a pilot study in Palestine.
Jamous RM; Sweileh WM; Abu-Taha AS; Sawalha AF; Zyoud SH; Morisky DE
Int J Clin Pharm; 2011 Dec; 33(6):942-8. PubMed ID: 21918840
[TBL] [Abstract][Full Text] [Related]
11. First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence.
Ferraro D; Camera V; Baldi E; Vacchiano V; Curti E; Guareschi A; Malagù S; Montepietra S; Strumia S; Santangelo M; Caniatti L; Foschi M; Lugaresi A; Granella F; Pesci I; Motti L; Neri W; Immovilli P; Montanari E; Vitetta F; Simone AM; Sola P
Curr Med Res Opin; 2018 Oct; 34(10):1803-1807. PubMed ID: 29526118
[TBL] [Abstract][Full Text] [Related]
12. Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study).
Fernández O; Duran E; Ayuso T; Hernández L; Bonaventura I; Forner M;
PLoS One; 2017; 12(10):e0185766. PubMed ID: 29049356
[TBL] [Abstract][Full Text] [Related]
13. Examining the relationship between antihypertensive medication satisfaction and adherence in older patients.
Al-Ruthia YS; Hong SH; Graff C; Kocak M; Solomon D; Nolly R
Res Social Adm Pharm; 2017; 13(3):602-613. PubMed ID: 27493129
[TBL] [Abstract][Full Text] [Related]
14. Satisfaction, Adherence and Health-Related Quality of Life with Transdermal Buprenorphine Compared with Oral Opioid Medications in the Usual Care of Osteoarthritis Pain.
Conaghan PG; Serpell M; McSkimming P; Junor R; Dickerson S
Patient; 2016 Aug; 9(4):359-71. PubMed ID: 27314487
[TBL] [Abstract][Full Text] [Related]
15. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
[TBL] [Abstract][Full Text] [Related]
16. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Picconi O; Cilia S; Cottone S; Centonze D; Gasperini C;
Mult Scler; 2011 Aug; 17(8):991-1001. PubMed ID: 21502310
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Motor Disability and the Level of Fatigue on Adherence to Therapeutic Recommendations in Patients with Multiple Sclerosis Treated with Immunomodulation.
Ślusarz R; Olkiewicz J; Bonek R; Filipska K; Biercewicz M; Wiśniewski A
Int J Med Sci; 2021; 18(15):3609-3614. PubMed ID: 34522188
[No Abstract] [Full Text] [Related]
18. Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea.
Byun DW; Moon SH; Kim T; Lee HH; Park HM; Kang MI; Ha YC; Chung HY; Yoon BK; Kim TY; Chae SU; Shin CS; Yang KH; Lee JH; Chang JS; Kim SH; Kim IJ; Koh JM; Jung JH; Yi KW; Yoo JJ; Chung DJ; Lee YK; Yoon HK; Hong S; Kim DY; Baek KH; Kim HJ; Kim YJ; Kang S; Min YK
J Bone Miner Metab; 2019 May; 37(3):563-572. PubMed ID: 30238428
[TBL] [Abstract][Full Text] [Related]
19. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Calkwood J; Cree B; Crayton H; Kantor D; Steingo B; Barbato L; Hashmonay R; Agashivala N; McCague K; Tenenbaum N; Edwards K
BMC Neurol; 2014 Nov; 14():220. PubMed ID: 25424122
[TBL] [Abstract][Full Text] [Related]
20. Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional study.
Al-Keilani MS; Almomani BA
Int J Pharm Pract; 2023 Apr; 31(2):198-205. PubMed ID: 36738264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
